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ABSTRACT
Curcumin (from curry) (C) is highly potent against cervical cancer cells (CCC), 
but poor bioavailability has limited its clinical use. Similar natural polyphenols 
resveratrol (from grapes) (R), and epicatechin gallate (from green tea) (E) also display 
activity against CCC. By treating CCC (HeLa) with C, E, or R, or combinations of these 
compounds, we computed combination indices and observed a strong synergism among 
C, E, and R at the unique molar ratio 4:1:12.5. This combination, named as TriCurin, 
rapidly down regulated HPV18 E6 and NF-kB expression while concomitantly inducing 
the tumor suppressor protein p53 in HeLa cells. In the mouse c-Ha-ras and HPV16 E6, 
E7-expressing TC-1 CCC, both C and TriCurin elicited suppression of E6, induction of 
both p53 and acetyl-p53 (activated p53), and activation of caspase-3, but the TriCurin-
evoked changes were several-fold greater than that produced by curcumin (4.7-fold 
for E6 inhibition, and 2-fold, 6-fold, and 1.7-fold for the induction of p53, acetyl-p53, 
and active caspase-3, respectively). Consequently, TriCurin was more potent in killing 
TC-1 and HeLa cells. Intralesional TriCurin treatment of tumors generated in mice by 
subcutaneously implanting the TC-1 CCC caused an 80–90% decrease in tumor growth. 
The ability of C to eliminate HeLa cells was significantly stabilized when delivered as 
TriCurin than when delivered alone. Topical application of TriCurin dispersed in a cream 
base afforded efficient transfer of C across the skin. Subcutaneous TriCurin injection 
yielded no adverse effect in tumor-naïve healthy mice. Thus, TriCurin is a safe and 
promising therapeutic agent against HPV-associated disease.
INTRODUCTION
The human papillomavirus (HPV) is the prime 
risk factor for cervical cancer that claims numerous lives 
worldwide and poses a major threat to females especially 
in the developing countries [1]. Majority of sexually 
active women acquire HPV by the age of 50, which 
makes cervical HPV infection the most common sexually 
                                                        Research Paper
Oncotarget60905www.impactjournals.com/oncotarget
transmitted disease in the U.S. [2]. The incidence of cervical 
cancer is rather low in the developed countries because 
of extensive screening programs, but the prohibitive 
cost of these programs make them inappropriate for the 
developing world [3]. Although the availability of two 
vaccines, Cervarix® or Gardasil® [4], offer prophylactic 
measures against the most common oncogenic HPV types 
16/18-associated cervical lesions, effective therapeutic 
measures for post-infection lesions are not currently 
available. Furthermore, such vaccination programs are not 
suitable for developing countries with limited resources. 
During the past decade, our group has been developing 
diverse strategies of potentiating the culinary component, 
curcumin (C), against cancer cells in culture and also in 
mouse models of melanoma, glioblastoma, and HPV+ 
cervical cancer [5–9]. However, due to its hydrophobicity 
and rapid breakdown in vivo, curcumin per se has not been 
an effective therapeutic agent [10, 11]. Using our expertise in 
targeting curcumin we initially addressed the global menace 
of HPV infection and cervical cancer by developing and 
testing a curcumin-based cervical cream and demonstrated its 
efficacy in eliminating cervical cancer cells [5]. In the current 
study, we have further potentiated the antitumor efficacy of 
curcumin through a simple strategy, which involves mixing 
of curcumin with two other polyphenols, epicatechin gallate 
(E) and resveratrol (R), at a unique synergistic molar ratio. 
As an ingredient of green tea, epicatechin gallate displays 
toxicity toward a wide range of cancer cells [12], and, unlike 
curcumin, it is soluble in water. An important component 
of grapes, resveratrol is known for its anti-oxidant, anti-
inflammatory, and anti-cancer properties [13]. Earlier studies 
have also shown that resveratrol functions in synergism with 
curcumin against cancer cells [14]. Our unique mixture of 
C, E, and R (named as TriCurin) shows sharply increased 
antitumor effects both in vitro as well as in vivo and can be 
applied in a cream base as a safe anticancer agent that readily 
permeates through the skin. Thus, we report here the design, 
mechanism of action, and application of a potentiated form 
of curcumin, TriCurin, as a promising therapeutic agent 
against HPV-associated neoplasia. 
RESULTS
Combination index measurement to obtain a 
synergistic ratio of C, E, and R
The IC50 for C (17 µM) for HeLa cells was obtained 
earlier using WST-1 assays [5]. In the current study, we 
similarly obtained 15.5 mM and 64.6 mM as IC50 values for 
E and R (for HeLa cells), respectively (Figure 1A and 1B). 
Next, we conducted several pilot experiments to determine 
the vulnerability of HeLa cells to those concentrations of 
C, E, and R that were at or below their individual IC50 
values. Our initial experiments using a mixture of C, E, 
and R at their IC50 concentrations revealed toxicity even 
toward normal human fibroblasts. Then, by using sub-IC50 
concentrations of E while holding the concentration of R at 
100 µM a ratio of C:E:R: 32 µM: 8 µM: 100 µM (or C:E:R 
in the molar ratio of 4:1:12.5) was obtained that showed 
selective toxicity toward cancer cells. At doses C:E:R: 
4:1:12.5, C:E:R: 8:2:25, and C:E:R: 16:4:50, the fractions 
of HeLa cells affected by the combination was greater than 
that observed with each of the individual components C, 
E, or R or the double combinations CE or CR (Figure 1C, 
1D, and 1E). This ratio was named as TriCurin and the 
increasing doses of C:E:R: 4:1:12.5, C:E:R: 8:2:25, 
C:E:R: 16:4:50, and C:E:R: 32:8:100 were dubbed as 4 
µM+, 8 µM+, 16 µM+, and 32 µM+ respectively. We next 
analyzed our data in the fraction of HeLa cells affected 
(killed) through Combination Index (CI) determination 
using the COMPUSYN software package from ComboSyn, 
Inc. (www.combosyn.com) and a strategy reported by 
Chou [15]. A synergism among the components of TriCurin 
at 8 µM+ and 32 µM+ was revealed when the CI at each 
of these doses was found to be less than 1 (Figure 1G). In 
sharp contrast, equal proportions of C, E, and R were either 
antagonistic (CI >> 1) or additive (CI = 1) (Figure 1G).
TriCurin is more potent than curcumin in killing 
both TC-1 and HeLa cells
In WST-1 assays, TriCurin displayed a 2.7-fold 
lower IC50 than C alone for the c-Ha-ras and HPV16 E6, 
E7-expressing mouse TC-1 cervical cancer cells [16] and 
a 4-fold lower IC50 than C alone for HeLa cells (Table 1). 
TriCurin treatment boosts p53 expression, 
suppresses NF-kB, and suppresses E6 expression 
in HeLa cells
We have shown earlier that 50-µM curcumin treatment 
causes a dramatic induction of the cell cycle inhibitor p53 and 
suppression of the pro-tumor protein NF-kB in the HeLa cells 
[5]. In these experiments, we observed only a partial induction 
of p53 at 32 µM C alone. However, delivering 32-µM C 
along with 8-µM E and 100-µM R (i.e. TriCurin) caused a 
more dramatic induction of p53 within 8 hours (Figure 2). 
In this case even the combinations CE and CR caused an 
induction of p53, but from three experiments, the induction 
in p53 was most significant with TriCurin and CR (Figure 
2B). Concomitantly, a sharp decrease in NF-kB expression 
was observed in the HeLa cells following treatment with 
TriCurin or CE (Figure 2C). Immunocytochemical analysis 
of TriCurin-treated HeLa cells revealed a dramatic inhibition 
of HPV E6 expression (Figure 2D–2F).
Although we initially used the human cervical 
cancer cell line HeLa to invent the potentiated 
formulation of curcumin (TriCurin), our major objective 
was to test the anticancer efficacy of TriCurin in a mouse 
model implanted with the mouse c-Ha-ras and HPV16 
E6, E7-expressing TC-1 cells [16]. Therefore, it was 
imperative for us to delineate the possible mechanism 
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of TriCurin-evoked elimination of TC-1 cells. In normal 
cells, the histone acetyltransferase (HAT) p300 and its 
co-activator CBP bind to the cell cycle inhibitor P53 to 
cause its activation through p300-mediated acetylation 
[17]. In HPV+ cancer cells, the oncoprotein E6 disrupts 
this P53-p300-CBP interaction by binding to both CBP 
and p300 and rendering them less effective to cause p53 
activation [18]. Thus, suppression of E6 expression in 
the cancer cells would be expected to trigger activation 
of p53 through p300-mediated acetylation of p53, 
and p53-dependent expression of Bax, which triggers 
apoptosis [19]. We treated cultured TC-1 cells with 
vehicle, 32-mM+ TriCurin, or 32-mM curcumin and 
performed a mechanistic analysis by immunostaining 
for E6, active caspase-3, p53, and acetyl-p53 
(Supplementary Figure S1).
TriCurin is significantly more potent than 
curcumin in causing suppression of E6 and 
activation of caspase-3 in TC-1 cells
As expected based on the mechanisms discussed 
above, compared to the vehicle-treated TC-1 cells, 
TriCurin (32 mM+) treatment for 6 h caused a 19-fold 
inhibition of E6 and a 9.7-fold activation of the mediator of 
apoptosis caspase-3 (Figure 3C, 3F, 3I, 3J–3L). Although 
32-mM curcumin alone also caused E6 suppression and 
caspase-3 activation, 32-mM+ TriCurin elicited 4.7-times 
greater suppression of E6 (Figure 3L) and 1.7-fold higher 
activation of caspase-3 (Figure 3B, 3E, 3H–3K) than 
32-mM curcumin alone after 6-h of treatment. 
TriCurin is significantly more potent than 
curcumin in activating P53 in TC-1 cells
Concomitant with E6 suppression, 32-mM+ TriCurin 
treatment for 6 h caused an induction as well as activation 
of P53 (Figure 4C, 3F, 3I, 3J–3L). Thus, compared to 
vehicle-treatment, TriCurin treatment elicited a 13-fold 
induction of P53 (P53 staining normalized to HOECHST) 
(Figure 4K), and a 49-fold activation of P53 (Acetyl P53 
staining normalized to P53 staining) (Figure 4J), thereby 
resulting in a 637-fold increase in the overall level of 
activated P53 (acetyl-P53 normalized to HOECHST) 
(Figure 4L). Although, compared to vehicle treatment, 
32-mM curcumin treatment of TC-1 cells also caused an 
Table 1: Tricurin is more potent in eliminating both TC-1 and HeLa cells
Cell Lines Curcumin Tricurin
IC50 (µM) IC50 (µM)
TC-1 35 13
HeLa 17 4
Figure 1: Fraction of cells affected by C, E, R, CE, CR, and CER: measurement of combination index to identify a 
synergistic formulation. (A) and (B) Concentration-dependent elimination of HeLa cells by epicatechin gallate (E) and resveratrol (R), 
respectively. (C–F) Fractions of HeLa cells killed by CER at 4 μM+, 8 μM+, 16 μM+, 32 μM+, and the corresponding concentrations of 
C, E, R, CE, and CR. (G) Combination index (CI) >> 1 for equimolar proportion of C:E:R: 8 μM:8 μM:8 μM (the components antagonize 
one another). At CI = 1 for C:E:R: 32 μM:32 μM:32 μM, the components had an additive effect. At CI < 1 for C:E:R: 8 μM:2 μM:25 μM 
and C:E:R: 32 μM:8 μM:100 μM, the components are synergistic. 
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induction and activation of P53 (Figure 4B, 4E, 4H, 4J–4L), 
at 6 h, TriCurin treatment yielded a two-fold higher 
induction of p53 (Figure 4K), and a three-fold higher 
activation of p53 (Figure 4J), thereby eliciting a six-fold 
higher level of activated p53 than yielded by 32-mM 
curcumin alone (Figure 4L).
Intralesional administration of TriCurin causes a 
dramatic inhibition of TC-1 tumors
Anti-tumor potency of TriCurin was demonstrated 
in vivo using a mouse model implanted (subcutaneously) at 
the nape of the neck with the mouse cell line TC-1. Based 
on the variation among volumes calculated from external 
dimensions of tumors and from water displacement of 
extricated tumors, intralesional administration of TriCurin 
into growing tumors was observed to cause an 80–90% 
decrease in tumor growth (Figure 5).
The cytotoxic activity of curcumin toward HeLa 
cells is stabilized when present as a mixture in 
TriCurin
In order to test if the antitumor activity of C was 
stabilized in the presence of E and R in TriCurin, we 
incubated C alone or as TriCurin in serum-free medium 
followed by treatment of HeLa cells with the medium. C, 
incubated as TriCurin, but not as CE or CR or C alone 
retained most of its potency to kill HeLa cells after 
24 hours (Figure 6). 
Additionally, we used the fluorescence from 
C at 540 nm (emission) to image cells. We observed 
that C from TriCurin was taken up by HeLa cells more 
rapidly than from C alone (Supplementary Figure S2- 
Supplementary Materials). Furthermore, following 
incubation of C or TriCurin in the culture medium 
overnight at 37°C, C from TriCurin was taken up more 
Figure 2: TriCurin causes restoration of p53 and suppression of NF-kB and E6 in HeLa cells. HeLa cells in culture were 
treated with drugs for 8 h for Western blotting and for 6 h for immunocytochemistry. (A) and (B) Cells treated with the corresponding CR 
and CER (32 μM+ TriCurin) show a significant increase in p53 expression. (A) and (C) Cells treated with CE and CER (32 μM+ TriCurin) 
display a significant decrease in NF-kB expression in (*p < 0.05). (D–F) E6 expression is significantly suppressed following 32 μM+ 
TriCurin treatment (p = 0.0008) (Data expressed as mean ± S.E.M).
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efficiently than from C alone (Supplementary Figure S1). 
These in vitro data support the use of TriCurin as an 
efficient strategy of delivering curcumin.
TriCurin administration into tumor-naïve mice 
causes no toxic effect
To test if TriCurin administration had any toxic 
effect on normal tissue, tumor-naïve mice were injected 
with vehicle or TriCurin (10 µl of 1.28 µM+ TriCurin) 
subcutaneously at the nape of the neck, every 72 hours 
for two weeks. Dissection of the injection area followed 
by H&E staining and pathologic examination revealed no 
sign of heightened cell death following TriCurin treatment 
as compared to the vehicle-injected tissue (Figure 7).
Topical application of a cream formulation 
of TriCurin allows permeation of curcumin 
through the skin layer within 20 hours
To evaluate the therapeutic applicability of TriCurin 
in the form of a topical or vaginal cream, we applied a 
uniform mixture of 20% TriCurin in a topical cream base 
VanPen (TriCurin-VanPen) on the shaven skin of mice. 
After 20 hours, the mice were terminated by injecting 
ketamine-xylazine, the skin from the application site 
removed, sectioned into transverse sections across the 
thickness of the skin, and the sections examined at 540 
nm (emission) using a confocal microscope. As shown in 
Figure 8, complete permeation of C, which is fluorescent, 
was observed across the entire thickness of the skin. 
Figure 3: TriCurin is more potent than curcumin in causing suppression of E6 and activation caspase-3 in TC-1 cells. 
TC-1 cells in triplicate wells were treated with vehicle, or 32-μM curcumin, or 32-μM+ TriCurin for 2, 4, and 6 hours, fixed, and then 
subjected to immunocytochemistry. (A, D, G) High E6 expression (green) and negligible active caspase-3 (red) observed after 2, 4, and 
6 h of vehicle treatment. (B, E, H) Curcumin elicits a pronounced decrease in E6 and a dramatic increase in active caspase-3. (C, F, I) 
TriCurin yields a more dramatic suppression of E6 and increase in caspase-3 than curcumin. Scale bar: 150 μm. (J–L) Quantification of 
staining intensities from triplicate samples (two images per sample) and normalization to the corresponding HOECHST staining intensities 
shows a time-dependent decrease in E6 and a progressive increase in active caspase-3 following curcumin or TriCurin treatment. Both 
changes appear significantly more pronounced with TriCurin. P-values: *, **, or ***, or #: E6 levels after drug treatment compared to 
vehicle-treated control (J and K) or when comparing between curcumin and TriCurin (L). Δ, Δ Δ, or Δ Δ Δ: active caspase-3 levels after drug 
treatment with respect to vehicle-treated control (J and K). *Δ: p <0.04 **Δ Δ: p < 0.02 ***Δ Δ Δ: p < 0.03; #p < 0.01. Data expressed as 
mean ± S.E.M.
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We also diluted 1 ml of the 20% TriCurin-VanPen 
(163 mM+ in TriCurin) 5000-fold in cell culture medium 
to achieve 32 mM+ TriCurin, from which decreasing 
concentrations of TriCurin were obtained by serial 
dilution for the treatment of HeLa cells in culture. 
Subsequent WST-1 assays faithfully reproduced the IC50 
values observed with free TriCurin (Table 1), whereas 
similarly diluted VanPen had no effect on the HeLa cells. 
Thus, TriCurin does not lose its antitumor activity in the 
TriCurin-VanPen formulation.
DISCUSSION 
In the current study, we have improved the efficacy 
of curcumin (C) as a therapeutic agent against HPV 
infection and cancer by combining it with two other 
polyphenols at a unique proportion to yield a synergistic 
combination, named TriCurin. The crucial factor for this 
synergism is the proportion of the three polyphenols 
in TriCurin (C:E:R: 4:1:12.5). While maintaining this 
proportion, increased efficacy of TriCurin over and above 
each of the three components and CE or CR was observed 
at 4 mM+, 8 mM+, and 16 mM+, beyond which individual 
polyphenols, CE, CR, as well as TriCurin approached a 
plateau revealing the elimination of almost all HeLa cells 
in in vitro cultures (Figure 1). 
HPV E6 inhibits P53 through two mechanisms, one 
of which entails P53 ubiquitination and degradation via 
E6-P53 association [20]. A second pathway involves E6 
binding to histone acetyltransferease (HAT) p300 and 
its co-activator CBP, thereby inhibiting the ability of 
p300 to activate the transcriptional activity of both p53 
as well as NF-kB [18]. However, NF-kB affords tumor 
cell protection by inducing Bcl-2 expression, whereas p53 
promotes apoptosis by boosting the expression of the pro-
apoptotic protein Bax [21]. Curcumin causes inactivation 
Figure 4: TriCurin is more potent than curcumin in regulating p53 in TC-1 cells. After vehicle or drug treatment of TC-1 cells 
(as described in Figure 3), the cells were probed for p53 (green) and acetyl-379K-p53 (red). (A, D, G) Vehicle-treated cells show virtually no 
p53 or acetyl-p53. (B, E, H) Curcumin treatment causes an increase in both p53 as well as acetyl-p53 over time. (C, F, I) TriCurin elicits 
a more dramatic increase in both p53 as well as acetyl-p53 compared to curcumin. Scale bar: 150 μm. (J) Normalization of acetyl-p53 to 
total p53 reveals a progressive increase in acetylation of p53 (activation) after curcumin or TriCurin treatment (compared to vehicle-treated 
control), but TriCurin elicits a three-fold higher activation than curcumin after 6 h. (K) A pronounced increase in p53 expression (induction) 
is observed compared to the vehicle-treated control in both curcumin as well TriCurin-treated cells, but a two-fold higher induction is 
observed with TriCurin than with curcumin after 6 h of treatment. (L) The combination of activation and induction of p53 yields an overall 
induction in active p53 after either curcumin or TriCurin treatment. TriCurin yields a six-fold higher induction in active p53 than curcumin 
after 6 h (p < 0.005). P-values: (compared to vehicle-treated control): #p < 0.01; ▲: p < 0.005. Data expressed as mean ± S.E.M.
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of the transcription factors AP-1 and NF-kB, which have 
been implicated in the transcription of HPV-associated 
proteins such as E6 and E7 [22]. This curcumin-evoked 
inhibition of NF-kB and the consequent suppression of E6 
[21], leads to induction of p53, suppression of the NF-
kB-Bcl-2 protective pathway, and preferential stimulation 
of the p53-Bax apoptotic pathway in cancer cells [19]. 
Corroboratively, we observed a dramatic activation of 
caspase-3 concomitant with 32-mM+ TriCurin-evoked 
suppression of E6 in the TC-1 cells (Figure 3). The 
suppression of E6 and activation of caspase-3 was also 
observed in the presence of 32-mM C, but the TriCurin 
effect was several-fold greater than that yielded by C 
alone (Figure 3). According to the studies discussed 
above the TriCurin-evoked suppression of E6 should cause 
decreased degradation of p53. Accordingly, we observed a 
13-fold induction of p53 in the 32-mM+ TriCurin-treated 
TC-1 cells with respect to the vehicle-treated cells (Figure 
4). It is known that C-terminal acetylation of p53 by the 
HAT p300 boosts p53’s transcriptional activity [17, 23]. 
Correspondingly, 32-mM+ TriCurin caused a 49-fold 
increase in acetyl-p53 with respect to the vehicle-treated 
control (when normalized to total p53) (Figure 4J), but 
since the total p53 expression had also increased by 13-
fold, the overall increase in acetyl-p53 was 637-fold 
with respect to the vehicle-treated control (Figure 4L). 
Curcumin (32 mM) treatment also caused suppression of 
E6, activation of caspase-3, and induction in p53 as well 
as acetyl-p53 with respect to vehicle treatment of TC-1 
cells, but the TriCurin-evoked changes were dramatically 
greater in each case. Based on the reports discussed 
earlier, our findings indicate that TriCurin or curcumin-
evoked suppression of E6 releases p53 from its inhibitory 
influence thereby allowing active p53 to trigger apoptosis 
in the TC-1 cells (Supplementary Figure S1). 
The reason why TriCurin is strikingly more potent 
than curcumin is not fully clear. Data presented in Figure 
6 and Supplementary Figure S2 indicate that this higher 
potency of TriCurin could be due to a combination of 
stabilization as well as increased uptake of C into cells. 
The current study presents a systematic analysis of 
combination indices to arrive at this synergistic, highly 
potent and unique anticancer formulation (TriCurin), but 
further theoretical and spectroscopic analyses are required 
to understand how curcumin, resveratrol, and epicatechin 
gallate at this unique molar ratio interact with one another 
to yield the dramatically higher anticancer and anti-HPV 
properties of TriCurin.
In the animal studies, high efficacy of tumor 
elimination was observed when aliquots of a 1.28 
mM+ TriCurin were injected into the tumor to yield an 
intra-tumor concentration of approximately 64 mM+. 
Figure 5: Intralesional TriCurin treatment causes a dramatic inhibition of TC-1 tumor growth in mice. (A) Volumes of 
extricated tumors from vehicle-treated and 64 μM+ TriCurin-treated mice (as measured by the displacement of water on the day of sacrifice) 
(day 10). The largest, intermediate, and smallest tumors in each group are shown here. (B) Estimated volumes from external measurement 
of tumors from vehicle-treated (n = 8) and TriCurin-treated (n = 9) mice. *p = 0.0003. **p = 0.00001 (Data compared between vehicle-
treated and TriCurin-treated on each day by two-tailed t-test with unequal variance and expressed as mean ± S.E.M).
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A dramatic inhibition of TC-1 tumor growth was observed 
with TriCurin. Similar application of TriCurin to tumor-
naïve mice had no adverse effect on normal tissue. With 
the objective of using TriCurin for topical application, we 
tested our cream formulation TriCurin-VanPen, which 
contained 20% TriCurin solubilized in the widely used 
cream base VanPen. Application of this TriCurin-VanPen 
to mouse skin demonstrated complete penetration of 
curcumin within 20 hours, thus justifying the possibility of 
its use in topical applications to eliminate warts. Recently, 
we have also developed a cream base with FDA-approved 
composition for vaginal application. Our formulation of 
TriCurin in this cream base will be tested in a human trial 
for HPV+ cervical dysplasia.
HPV infection leading to cervical cancer has 
reached almost an epidemic level in many parts of the 
developing world where appropriate vaccination programs 
are not affordable for the pre-infection individuals and 
screening programs are not available for the HPV-
infected men and women. Although HPV infection clears 
spontaneously with time in most younger women [24], 
some older individuals become persistently HPV+ even in 
the developed countries. In women, loop electrosurgical 
excision procedure (LEEP) is commonly used to treat 
high-grade dysplasia. Though highly effective, LEEP is 
associated with the risk of cervical incompetence and 
preterm delivery [25]. 
In the midst of this serious global health problem 
due to HPV infection, TriCurin comes as a relatively 
less expensive but highly effective therapeutic 
alternative. It potently suppresses HPV E6 expression 
(Figure 3), efficaciously eliminates HPV+ cells in 
culture (Figure 1, Table 1), and suppresses HPV E6 
and E7+ TC-1 tumors in a dramatic manner (Figure 5). 
When incubated in the culture medium, curcumin 
alone rapidly loses its ability to eliminate HeLa cells, 
but in the TriCurin formulation, curcumin retains its 
efficacy to eliminate HeLa cells (Figure 6). Based on 
such properties, the use of TriCurin and its appropriate 
formulations come as a relatively inexpensive but 
highly promising therapeutic approach to treat HPV 
infections and cervical cancer. 
Figure 6: Epicatechin gallate and resveratrol stabilize curcumin’s ability to eliminate HeLa cells. Freshly prepared media 
containing C (32 μM), E (8 μM), R (100 μM), CE, CR, CER, and an identical set of media incubated at 37°C for 24 h were used to 
treat HeLa cells for 48 h followed by WST-1 assay. Data shown are representative of three independent experiments, each of which was 
performed using triplicate samples and the results were expressed as mean ± SEM (*p ≤ 0.05 with respect to the effect of the freshly-
prepared drug). The differences between the effects of freshly-prepared and incubated CER and also between incubated C and incubated 
CER were insignificant (two-tailed t-test with unequal variance). 
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Figure 7: TriCurin is non-toxic to tumor-naïve mouse tissue. H&E staining of tissue sections from the neck region of tumor-naïve 
mice. (A) Vehicle treated mouse. (B) Mouse injected subcutaneously five times, every 72 hours, with 1.28 mM+ TriCurin (at the nape of 
the neck). Enlarged views shown on the right.
Figure 8: TriCurin-VanPen applied topically allows permeation of curcumin through the skin. VanPen or 20% TriCurin-
VanPen were applied on shaven skin at the nape of the neck. After 20 h skin sections were examined using confocal microscopy. (A) 




Mice (C57BL6) were handled and used according to 
an experimental protocol that followed NIH guidelines for 
animal use and was approved by the Institutional Animal Care 
Committee (IACUC) of the College of Staten Island (CUNY).
TC-1 cells
Originally created by retroviral transduction of 
primary lung epithelial cells from C57BL/6 mice to 
express the oncogenes HaRas, HPV16 E6 and E7, the 
TC-1 cell line was a kind gift from Prof. T.-C. Wu (Johns 
Hopkins Medical Institutions, Baltimore) [16].
Determination of IC50 for curcumin using WST-
1 assay
TriCurin was serially diluted into DMEM plus 
1× insulin-transferrin-selenium (ITS) supplement 
(Invitrogen) and was added to the cells in 50-µl aliquot/
well. Subsequent to TriCurin treatment in triplicate wells 
for 96 hours, the medium was aspirated, the cells rinsed 
three times with PBS, and then 50 µl of 10% WST-1 
(Clontech, Mountain View, CA) in DMEM was added to 
each well. The plate was incubated at 37°C for 45 min 
and absorbance monitored at 440 nm using a plate reader. 
Results obtained were converted to percent control and 
then analyzed using GraphPad Prism.
TriCurin
 Curcumin (C) (≥ 98% curcuminoid content) (CAS 
number 458-37-7) (Thermo Fisher Scientific, New Jersey, 
U.S.A.; prepared by Acros Organics for Thermo Fisher; 
stored at room temperature under nitrogen), (-)-epicatechin 
gallate (E), and resveratrol (R) (Thermo Fisher) at the molar 
proportion C:E:R: 4:1:12.5 was prepared at various doses. 
A dose that contained C: E: R: (in µM) 32: 8: 100, was 
named as 32 µM+ TriCurin. First a solution of 1.28 mM+ 
TriCurin in PBS plus 5% DMSO was prepared by dilution 
from solutions of C and R in DMSO and a solution of E 
in PBS. Then, 64 µM+, 32 µM+, 16 µM+, 8 µM+, 4 µM+ 
TriCurin solutions were prepared through serial dilution of 
the 1.28 mM+ in serum-free culture medium or PBS. The 
first two dilutions required addition of small increments 
(2 µl) of the stock solution into an appropriate volume of 
medium or PBS with vigorous and continuous vortexing. 
Determination of combination index using the 
COMPUSYN software package
Dose response analysis for each polyphenol (C, 
E, and R) and the combinations CE, CR, and CER was 
performed using the HeLa cells. Fraction affected at each 
concentration of C (in mM: 4, 8, 16, 32), at each of the 
corresponding concentrations of E (in mM: 1, 2, 4, 8), R 
(in mM: 12.5, 25, 50, 100), and at each of the combinations 
CE, CR, and CER at the increasing combined doses was 
determined. This series of data (Fractions affected) were 
next analyzed using the COMPUSYN software package 
from ComboSyn, Inc. (www.combosyn.com) to determine 
the combination index at each of the increasing doses of 
CER (4 mM+, 8 mM+, 16 mM+, 32 mM+) [15]. Using a 
similar approach, combination indices for equal ratios 
C:E:R: 8 mM: 8 mM: 8 mM and C:E:R: 32 mM: 32 mM: 32 
mM were also determined.
Western blot analysis
Cells were lysed in RIPA buffer (50 mM Tris-
HCl, pH 8.0, 1% NP-40, 0.5% deoxycholate, 0.1% 
SDS, 1 mM EDTA, 1 mM EGTA 1 mM PMSF, 50 mM 
NaF, 100 mM Na4P2O7, 10 mM Na β-glycerophosphate, 
1 mM Na3VO4, 1X protease inhibitor cocktail (Roche) 
and quantified by Lowry protein assay. Equal amounts 
of protein (20 μg) for all the cells described above were 
prepared by heating samples in loading buffer composed 
of 95% Laemmli sample buffer and 5% 2-mercaptoethanol 
(Sigma, St. Louis, MO) in boiling water for 5 min. The 
proteins were separated using 10% SDS polyacrylamide 
gel electrophoresis at 100 V for 1.5 h. The electrophoretic 
transfer of proteins onto a 0.45-μm nitrocellulose membrane 
was performed at 200 mA constant current for 2 h on ice. 
Primary antibody solutions were prepared in Tris-buffered 
saline containing Tween (T-TBS; 20 mM Tris buffer, pH 
7.4, 150 mM sodium chloride, 0.05 % Tween-20) and 1% 
non-fat dried milk and incubated overnight. The antibody 
against p53 (sc-6243) was obtained from Santa Cruz 
Biotechnology (Santa Cruz, CA) and a mouse monoclonal 
ß-actin antibody (SKU A2228) was procured from Sigma 
(St. Louis, MO). All the primary antibodies were used at 
a dilution 1:1000 except for the ß-actin antibody, which 
was used at a dilution of 1:5000. The secondary antibodies, 
anti-rabbit or anti-mouse were used at dilutions 1:40,000 
and 1:5000 respectively. The Western blot signals were 
visualized using enhanced chemiluminescence (Super 
Signal West Pico, Pierce, Rockford, IL) and digitally 
imaged with an Alpha Innotech imager (San Leandro, CA). 
The protein bands were quantified using ImageJ and the 
figures were arranged using Adobe Photoshop.
Immunocytochemistry
HeLa and TC-1 cells (60,000 cells per well) 
were plated in triplicate wells on poly-L-lysine-coated 
coverslips in 24-well plates and treated with drugs after 
the wells reached 80% confluence. All drug treatments 
were performed in serum-free DMEM containing 1% 
supplement (ITS) (insulin, transferrin, selenium; Gibco 
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BRL, Grand Island, NY). After treatment with 32 µM+ of 
TriCurin or C for the indicated times, cells were fixed in 
4% paraformaldehyde for 45 minutes at room temperature, 
rinsed with phosphate buffered saline (PBS) three times 
(15 min each), and blocked with 10% normal goat serum, 
0.1 % Triton X-100 in PBS for 2 h. The cells were then 
incubated overnight with anti-E6 antibody (sc-460, Santa 
Cruz Biotechnology, Dallas, TX) (1:75) in 2% normal 
goat serum, 0.1 % Triton X-100 in PBS. In mechanistic 
studies, the TC-1 cells were treated with anti-E6, anti-p53 
(sc-6243, Santa Cruz Biotechnology, Dallas, TX) (1:100), 
anti-acetyl-379K-p53 (GTX88013, GeneTex, Inc., Irvine, 
CA) (1:300), and anti-active caspase-3 (CST#9661, Cell 
Signaling Technology, Danvers, MA) (1:200) antibodies 
in a similar manner. The acetylated 379K position on mouse 
p53 is homologous to the 382K acetylation site on the 
human protein [26, 27]. Subsequent to primary antibody 
treatment, the cells were washed three times with PBS and 
then incubated with the respective secondary antibodies 
(Alexa Fluor® 488 goat anti–mouse IgG, Alexa Fluor® 488 
goat anti–rabbit IgG and Alexa Fluor® 568 goat anti–rabbit 
IgG antibodies) (Life Technologies Corp., Carlsbad, CA) 
in 2% normal goat serum, 0.1 % Triton X-100 in PBS 
(1:1000) for 3 h and then washed three times with PBS (15 
min each) followed by incubation with HOECHST33342 
(HOECHST) (10 µg/ml) in PBS (10 µM) for 30 min 
and three washes with PBS. The coverslips containing 
stained cells were mounted on slides and cell images were 
acquired using a Zeiss Axio Observer Z1 microscope and 
an AxioVision 4.6.3-AP1 camera at emission wavelengths 
of 460 nm (blue) 540 nm (green) and 580 (red). Images 
of two different, randomly chosen fields were acquired 
from each well for quantification. ImageJ (NIH, Bethesda, 
MD) was used to measure the E6, p53, acetyl-379K-p53, 
active caspase-3 and HOECHST fluorescence intensities. 
The fluorescence intensities of all the above-mentioned 
antibodies were normalized to HOECHST intensity (blue). 
Since p53 displayed both induction as well as acetylation-
mediated activation, the HOECHST-normalized staining 
intensities were expressed as acetyl-379K-p53/p53, p53/
HOECHST and acetyl-379K-p53/HOECHST.
In vivo studies to demonstrate anti-tumor 
activity of TriCurin
TC-1 cells generated by engineering mouse lung 
epithelial cells to ras and HPV16/18 E6 and E7 have 
been used earlier to generate preclinical mouse models 
of HPV+ cancer [16]. In our studies 50,000 TC-1 cells 
were implanted subcutaneously at the nape of the neck 
of two to three month-old C57BL6 mice. When the 
tumors assumed the approximate length of 0.5 cm, each 
tumor was marked into four quadrants and 2.5 µl of 
the 1.28 mM+ TriCurin solution was infused into each 
of the four quadrants every 72 hours (final estimated 
concentration in the tumor: 64 mM+). Intralesional 
1.28 mM+ TriCurin or vehicle (PBS plus 5% DMSO) 
treatment was conducted on days 1 (i.e. at approximate 
length of 0.5-cm), 4, and 7. Tumor dimensions were 
measured using a caliper before each treatment and in the 
end, 72 hours after the third TriCurin treatment (tumor 
dimension = length × width × height × 0.5). Subsequently, 
the mice were sacrificed, tumors extricated, and the final 
tumor volumes were measured again by displacement of 
water. 
Toxicity tests for TriCurin
Three 3-month-old female mice in each of two 
groups were administered (subcutaneously, at the nape of 
the neck) PBS, or 10 ml 1.28 mM+ TriCurin (every 72 
hours) for two weeks. Subsequently, the injection area 
of each mouse was dissected into tissue sections, which 
were stained with hematoxylin and eosin (H&E) for 
histopathologic examination by a pathologist (L.M.O).
Topical TriCurin-VanPen cream
Curcumin 1.5 g, Epicatechin Gallate 0.5 g, 
Resveratrol 3.0 g and 20.0 g VanPen base cream 
(Professional Compounding Centers of America, Inc., 
PCCA, Houston, TX) were mixed thoroughly as follows: 
10 g of VanPen was placed in the mixing chamber of a 
pharmaceutical-grade mixer (Electronic Mortar and 
Pestle Ungulator 2100 by GAKO International, München, 
Germany), C, E, R, powders were added to it, then 10 g 
of VanPen was added on top of the mixture, and the 
ingredients were mixed thoroughly with a motor-driven 
rod with blades until a uniform, yellow emulsion was 
obtained. This yielded approximately 25 ml of the 20% 
TriCurin-VanPen cream (163 mM+ in TriCurin).
Statistical analysis
Statistical analyses were performed using Microsoft 
Excel® 2007 (Microsoft Corporation, Redmond, WA) and 
GraphPad Prism® 5 (GraphPad Software, Inc., La Jolla, 
CA). Means and standard deviations were calculated for 
each treatment and converted to percent carrier-treated. 
Half maximal inhibitory concentration (IC50) values 
were obtained after performing regression analyses. 
Significance was assessed using two-tailed t-test with 
unequal variance for comparison between two groups 
and one-way ANOVA for comparison among three or 
more data sets using Tukey for post-hoc analysis. In both 
analyses, p < 0.05 was considered as significant. 
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